Alexion Pharmaceuticals Stock Fundamentals
Alexion Pharmaceuticals fundamentals help investors to digest information that contributes to Alexion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alexion Stock. The fundamental analysis module provides a way to measure Alexion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alexion Pharmaceuticals stock.
Alexion |
Alexion Pharmaceuticals Company Current Valuation Analysis
Alexion Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alexion Pharmaceuticals Current Valuation | 39.17 B |
Most of Alexion Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alexion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Alexion Pharmaceuticals has a Current Valuation of 39.17 B. This is 172.71% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all United States stocks is 135.62% lower than that of the firm.
Alexion Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alexion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Alexion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alexion Pharmaceuticals competition to find correlations between indicators driving Alexion Pharmaceuticals's intrinsic value. More Info.Alexion Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 2.28 of Return On Asset per Return On Equity. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alexion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Alexion Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alexion Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alexion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alexion Pharmaceuticals by comparing valuation metrics of similar companies.Alexion Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Alexion Fundamentals
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 | |||
| Profit Margin | 10.89 % | |||
| Operating Margin | 52.12 % | |||
| Current Valuation | 39.17 B | |||
| Shares Outstanding | 221.02 M | |||
| Shares Owned By Insiders | 0.34 % | |||
| Shares Owned By Institutions | 88.27 % | |||
| Number Of Shares Shorted | 8.46 M | |||
| Price To Earning | 58.24 X | |||
| Price To Book | 3.19 X | |||
| Price To Sales | 6.33 X | |||
| Revenue | 6.26 B | |||
| Gross Profit | 5.52 B | |||
| EBITDA | 3.26 B | |||
| Net Income | 681.8 M | |||
| Cash And Equivalents | 3.47 B | |||
| Cash Per Share | 15.70 X | |||
| Total Debt | 2.88 B | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 4.52 X | |||
| Book Value Per Share | 56.21 X | |||
| Cash Flow From Operations | 3.09 B | |||
| Short Ratio | 4.24 X | |||
| Earnings Per Share | 3.08 X | |||
| Price To Earnings To Growth | 1.46 X | |||
| Number Of Employees | 3.84 K | |||
| Beta | 1.28 | |||
| Market Capitalization | 39.66 B | |||
| Total Asset | 13.13 B | |||
| Retained Earnings | 5.01 B | |||
| Working Capital | 1.71 B | |||
| Current Asset | 2.43 B | |||
| Current Liabilities | 718.25 M | |||
| Z Score | 7.8 |
Pair Trading with Alexion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alexion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alexion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Alexion Stock
If you are still planning to invest in Alexion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alexion Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |